FDAsafety guidance66% confidence
FDA AP — XTANDI (SUPPL)
Source: FDA
Why This Matters
Why this matters: provides agency context on safety guidance that may shape timing or evidence expectations for ACADIA Pharmaceuticals; the same agency is already in play for this signal, so precedent weight is higher.
Regulatory Analysis
Application NDA213674. Sponsor: ASTELLAS. Submission status: AP. Submission type: SUPPL. Review priority: STANDARD. Active ingredients: ENZALUTAMIDE.
Supporting Context
- Therapeutic area
- Neurology · Parkinson's Disease
- Sub-indication
- General
Related signal: FDA grants priority review for NUPLAZID supplemental application